Methods for treating demodex blepharitis using lotilaner formulations
Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
1. A method for treating Demodex blepharitis, comprising topically administering directly to an ocular surface of one or more eyes of a human patient in need of treatment thereof an effective amount of an ophthalmic composition, wherein the ophthalmic composition comprises lotilaner and a pharmaceutically acceptable vehicle, and wherein the lotilaner is present at about 0.25% by weight with respect to the total weight of the composition administered.
2. The method of claim 1 , wherein the ophthalmic composition comprises an eye drop.
3. The method of claim 1 , wherein topically administering further comprises topically administering the ophthalmic composition at least once daily for at least about 4 weeks.
4. The method of claim 3 , wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient.
5. The method of claim 1 , wherein topically administering further comprises topically administering the ophthalmic composition at least twice daily for at least about 6 weeks.
6. The method of claim 5 , wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient.
7. The method of claim 1 , wherein topically administering further comprises topically administering the ophthalmic composition at least twice daily for at least about 90 days.
8. The method of claim 7 , wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient.
9. The method of claim 1 , wherein topically administering further comprises topically administering the ophthalmic composition at least three times daily for at least about 90 days.
10. The method of claim 9 , wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient.
11. A method for treating Meibomian gland dysfunction caused by Demodex infestation, comprising topically administering directly to one or more of the eye, eyelids, or eyelashes of a human patient in need of treatment thereof an effective amount of an ophthalmic composition, wherein the ophthalmic composition comprises lotilaner and a pharmaceutically acceptable vehicle, and wherein the lotilaner is present at about 0.25% by weight with respect to the total weight of the composition administered.
12. The method of claim 11 , wherein the ophthalmic composition comprises an eye drop.
13. The method of claim 11 , wherein topically administering further comprises topically administering the ophthalmic composition at least once daily for at least about 4 weeks.
14. The method of claim 13 , wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient.
15. The method of claim 11 , wherein topically administering further comprises topically administering the ophthalmic composition at least twice daily for at least about 6 weeks.
16. The method of claim 15 , wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient.
17. The method of claim 11 , wherein topically administering further comprises topically administering the ophthalmic composition at least twice daily for at least about 90 days.
18. The method of claim 17 , wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient.
19. The method of claim 11 , wherein topically administering further comprises topically administering the ophthalmic composition at least three times daily for at least about 90 days.
20. The method of claim 19 , wherein each administering further comprises topically administering between about 25 microliters and about 50 microliters of the ophthalmic composition to the patient.